TipRanks
Telix Pharmaceuticals Ltd. (MX:TLX1N)
:TLX1N
Mexico Market
TLX1N
Telix Pharmaceuticals
RESEARCH TOOLSreports

Telix Pharmaceuticals (TLX1N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

TLX1N Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Telix
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TLX1N Stock 12 Month Forecast

Average Price Target

$313.60
▲(3.65% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is $313.60 with a high forecast of $403.06 and a low forecast of $239.32. The average price target represents a 3.65% change from the last price of $302.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"238":"$238","321":"$321","404":"$404","279.5":"$279.5","362.5":"$362.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":403.05820416,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$403.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":313.60447397424,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$313.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":239.31580872,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$239.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[238,279.5,321,362.5,404],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302.55,310.28140032,318.01280064,325.74420096,333.47560128000003,341.2070016,348.93840192,356.66980224,364.40120256,372.13260288000004,379.8640032,387.59540352,395.32680384,{"y":403.05820416,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302.55,303.4003441518646,304.25068830372925,305.10103245559384,305.9513766074585,306.8017207593231,307.6520649111877,308.5024090630523,309.35275321491696,310.20309736678155,311.0534415186462,311.9037856705108,312.75412982237543,{"y":313.60447397424,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302.55,297.68583144,292.82166288,287.95749432,283.09332576,278.22915720000003,273.36498864,268.50082008000004,263.63665152,258.77248296,253.9083144,249.04414584,244.17997728,{"y":239.31580872,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":302.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.55,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$403.06Average Price Target$313.60Lowest Price Target$239.32
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on MX:TLX1N
David Stanton
Jefferies
Jefferies
$377.87→$403.06
Buy
33.22%
Upside
Reiterated
09/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Ord Minnett Analyst forecast on MX:TLX1N
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$258.84→$277.1
Buy
-8.41%
Downside
Reiterated
09/29/26
Ord Minnett Remains a Buy on Telix Pharmaceuticals (TLPPF)
UBS Analyst forecast on MX:TLX1N
David Low
UBS
UBS
$277.1
Buy
-8.41%
Downside
Reiterated
09/23/26
UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
Citi Analyst forecast on MX:TLX1N
Laura Sutcliffe
Citi
Citi
$390.46
Buy
29.06%
Upside
Reiterated
09/23/26
Citi Remains a Buy on Telix Pharmaceuticals (TLPPF)
Jarden Analyst forecast on MX:TLX1N
Steven Wheen
Jarden
Jarden
$264.51
Buy
-12.57%
Downside
Reiterated
09/22/26
Jarden Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Bell Potter Analyst forecast on MX:TLX1N
John Hester
Bell Potter
Bell Potter
$239.32
Buy
-20.90%
Downside
Reiterated
09/21/26
Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Canaccord Genuity Analyst forecast on MX:TLX1N
Shane Storey
Canaccord Genuity
Canaccord Genuity
$381.02→$396.76
Buy
31.14%
Upside
Reiterated
09/21/26
Canaccord Genuity Remains a Buy on Telix Pharmaceuticals (TLPPF)
RBC Capital Analyst forecast on MX:TLX1N
Craig Wong-Pan
RBC Capital
RBC Capital
$239.32→$264.51
Buy
-12.57%
Downside
Upgraded
09/21/26
Telix upgraded to Outperform from Sector Perform at RBC CapitalTelix upgraded to Outperform from Sector Perform at RBC Capital
Morgan Stanley Analyst forecast on MX:TLX1N
David Bailey
Morgan Stanley
Morgan Stanley
$301.03
Buy
-0.50%
Downside
Reiterated
09/15/26
Morgan Stanley Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
J.P. Morgan Analyst forecast on MX:TLX1N
Chris Cooper
J.P. Morgan
J.P. Morgan
$322.19
Buy
6.49%
Upside
Reiterated
09/14/26
Telix Pharmaceuticals (TLPPF) Gets a Buy from J.P. Morgan
TD Cowen Analyst forecast on MX:TLX1N
Tara Bancroft
TD Cowen
TD Cowen
$251.91
Buy
-16.74%
Downside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
CLSA Analyst forecast on MX:TLX1N
Andrew Paine
CLSA
CLSA
$305.44
Buy
0.96%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on MX:TLX1N
David Stanton
Jefferies
Jefferies
$377.87→$403.06
Buy
33.22%
Upside
Reiterated
09/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Ord Minnett Analyst forecast on MX:TLX1N
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$258.84→$277.1
Buy
-8.41%
Downside
Reiterated
09/29/26
Ord Minnett Remains a Buy on Telix Pharmaceuticals (TLPPF)
UBS Analyst forecast on MX:TLX1N
David Low
UBS
UBS
$277.1
Buy
-8.41%
Downside
Reiterated
09/23/26
UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
Citi Analyst forecast on MX:TLX1N
Laura Sutcliffe
Citi
Citi
$390.46
Buy
29.06%
Upside
Reiterated
09/23/26
Citi Remains a Buy on Telix Pharmaceuticals (TLPPF)
Jarden Analyst forecast on MX:TLX1N
Steven Wheen
Jarden
Jarden
$264.51
Buy
-12.57%
Downside
Reiterated
09/22/26
Jarden Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Bell Potter Analyst forecast on MX:TLX1N
John Hester
Bell Potter
Bell Potter
$239.32
Buy
-20.90%
Downside
Reiterated
09/21/26
Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Canaccord Genuity Analyst forecast on MX:TLX1N
Shane Storey
Canaccord Genuity
Canaccord Genuity
$381.02→$396.76
Buy
31.14%
Upside
Reiterated
09/21/26
Canaccord Genuity Remains a Buy on Telix Pharmaceuticals (TLPPF)
RBC Capital Analyst forecast on MX:TLX1N
Craig Wong-Pan
RBC Capital
RBC Capital
$239.32→$264.51
Buy
-12.57%
Downside
Upgraded
09/21/26
Telix upgraded to Outperform from Sector Perform at RBC CapitalTelix upgraded to Outperform from Sector Perform at RBC Capital
Morgan Stanley Analyst forecast on MX:TLX1N
David Bailey
Morgan Stanley
Morgan Stanley
$301.03
Buy
-0.50%
Downside
Reiterated
09/15/26
Morgan Stanley Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
J.P. Morgan Analyst forecast on MX:TLX1N
Chris Cooper
J.P. Morgan
J.P. Morgan
$322.19
Buy
6.49%
Upside
Reiterated
09/14/26
Telix Pharmaceuticals (TLPPF) Gets a Buy from J.P. Morgan
TD Cowen Analyst forecast on MX:TLX1N
Tara Bancroft
TD Cowen
TD Cowen
$251.91
Buy
-16.74%
Downside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
CLSA Analyst forecast on MX:TLX1N
Andrew Paine
CLSA
CLSA
$305.44
Buy
0.96%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
WSTWest Pharmaceutical Services
OMCLOmnicell
ACHVAchieve Life Sciences
LFMDLifeMD
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

3 Months
David StantonJefferies
Success Rate
17/21 ratings generated profit
81%
Average Return
+23.80%
Copying David Stanton's trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +23.80% per trade.
1 Year
Steven WheenJarden
Success Rate
24/28 ratings generated profit
86%
Average Return
+49.13%
Copying Steven Wheen's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +49.13% per trade.
2 Years
Steven WheenJarden
Success Rate
22/28 ratings generated profit
79%
Average Return
+88.66%
Copying Steven Wheen's trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +88.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLX1N Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
23
14
14
15
23
Buy
6
6
4
5
15
Hold
0
0
2
3
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
20
20
23
42
In the current month, TLX1N has received 38 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TLX1N average Analyst price target in the past 3 months is 313.60.
Each month's total comprises the sum of three months' worth of ratings.

TLX1N Financial Forecast

TLX1N Earnings Forecast

Next quarter’s earnings estimate for TLX1N is -$1.19 with a range of -$1.83 to -$0.72. The previous quarter’s EPS was $3.07. TLX1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TLX1N has Performed in-line its overall industry.
Next quarter’s earnings estimate for TLX1N is -$1.19 with a range of -$1.83 to -$0.72. The previous quarter’s EPS was $3.07. TLX1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TLX1N has Performed in-line its overall industry.

TLX1N Sales Forecast

Next quarter’s sales forecast for TLX1N is $8.94B with a range of $8.83B to $9.10B. The previous quarter’s sales results were $8.56B. TLX1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TLX1N has Performed in-line its overall industry.
Next quarter’s sales forecast for TLX1N is $8.94B with a range of $8.83B to $9.10B. The previous quarter’s sales results were $8.56B. TLX1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TLX1N has Performed in-line its overall industry.

TLX1N Stock Forecast FAQ

What is MX:TLX1N’s average 12-month price target, according to analysts?
Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 313.60.
    What is MX:TLX1N’s upside potential, based on the analysts’ average price target?
    Telix Pharmaceuticals Ltd. has 3.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Telix Pharmaceuticals Ltd. a Buy, Sell or Hold?
          Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Telix Pharmaceuticals Ltd.’s share price target?
            The average share price target for Telix Pharmaceuticals Ltd. is 313.60. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $403.06 ,and the lowest forecast is $239.32. The average share price target represents 3.65% Increase from the current price of $302.55.
              What do analysts say about Telix Pharmaceuticals Ltd.?
              Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Telix Pharmaceuticals Ltd.?
                To buy shares of MX:TLX1N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.